Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Petrelintide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Roche Backs Amylin Drug for Low-Side-Effect Obesity Care
    Roche Backs Amylin Drug for Low-Side-Effect Obesity Care

    23 Apr 2026

    // BIOSPACE

    https://www.biospace.com/business/roche-insists-amylin-obesity-drug-still-valuable-for-patients-who-dont-want-side-effects

    BIOSPACE
    23 Apr 2026
    Share Share
    Zealand's Zupreme serves up to 10.7% mean weight loss
    Zealand's Zupreme serves up to 10.7% mean weight loss

    06 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3250569/0/en/Zealand-Pharma-announces-positive-Phase-2-results-for-petrelintide-an-amylin-analog-with-potential-to-redefine-the-weight-management-experience-for-people-living-with-overweight-an.html

    GLOBENEWSWIRE
    06 Mar 2026
    Share Share
    Genentech Announces Positive Phase II Results for Petrelintide
    Genentech Announces Positive Phase II Results for Petrelintide

    05 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-05/genentech-announces-positive-phase-ii-results-for-petrelintide-an-amylin-analog-developed-for-peopl

    PHARMIWEB
    05 Mar 2026
    Share Share
    Roche Reports Positive Phase II Results For Petrelintide
    Roche Reports Positive Phase II Results For Petrelintide

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3250568/0/en/Roche-announces-positive-Phase-II-results-for-petrelintide-an-amylin-analog-developed-for-people-living-with-overweight-and-obesity.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share
    Zealand Pharma Announces Financial Results For The Full Year 2025
    Zealand Pharma Announces Financial Results For The Full Year 2025

    19 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/19/3240768/0/en/Zealand-Pharma-Announces-Financial-Results-for-the-Full-Year-2025.html

    GLOBENEWSWIRE
    19 Feb 2026
    Share Share
    Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36
    Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36

    10 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-selects-oral-amylin-receptor-peptide-agonist-asc36-for-clinical-development-302683756.html

    PR NEWSWIRE
    10 Feb 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.